Docetaxel-related interstitial pneumonitis
Docetaxel (Taxotere®) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10–20 days...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677769/ |
| id |
pubmed-4677769 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-46777692015-12-16 Docetaxel-related interstitial pneumonitis Wang, Chung-Jen Chang, Hou-Tai Chang, Cheng-Yu Case Report Docetaxel (Taxotere®) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10–20 days (median time: 18 days) after docetaxel administration. Here, we reported the case of a patient who had pulmonary toxicity of ILD within 3 days after using a relatively low-dose docetaxel administration. Although some articles have described patients who progressed to respiratory failure and needed intubation, this patient responded well to steroid treatment and discontinued docetaxel administration. Dove Medical Press 2015-12-09 /pmc/articles/PMC4677769/ /pubmed/26677333 http://dx.doi.org/10.2147/TCRM.S90488 Text en © 2015 Wang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Wang, Chung-Jen Chang, Hou-Tai Chang, Cheng-Yu |
| spellingShingle |
Wang, Chung-Jen Chang, Hou-Tai Chang, Cheng-Yu Docetaxel-related interstitial pneumonitis |
| author_facet |
Wang, Chung-Jen Chang, Hou-Tai Chang, Cheng-Yu |
| author_sort |
Wang, Chung-Jen |
| title |
Docetaxel-related interstitial pneumonitis |
| title_short |
Docetaxel-related interstitial pneumonitis |
| title_full |
Docetaxel-related interstitial pneumonitis |
| title_fullStr |
Docetaxel-related interstitial pneumonitis |
| title_full_unstemmed |
Docetaxel-related interstitial pneumonitis |
| title_sort |
docetaxel-related interstitial pneumonitis |
| description |
Docetaxel (Taxotere®) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10–20 days (median time: 18 days) after docetaxel administration. Here, we reported the case of a patient who had pulmonary toxicity of ILD within 3 days after using a relatively low-dose docetaxel administration. Although some articles have described patients who progressed to respiratory failure and needed intubation, this patient responded well to steroid treatment and discontinued docetaxel administration. |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677769/ |
| _version_ |
1613512540533293056 |